Fluorouracil prodrugs for the treatment of proliferative vitreoretinopathy: Formulation in silicone oil and in vitro release of fluorouracil

International Journal of Pharmaceutics

Volumn 259, Issue 1-2, 2003, Pages 181-192

  Jolimaître, Pascale ^a   Malet Martino, Myriam ^a,b   Martino, Robert ^a  

^a Université Paul Sabatier   (France)

^b UPS)   (France)

Author keywords

In vitro release of 5 fluorouracil; N1 Alkylcarbonyl 5 fluorouracil prodrugs; N1 Lauroyl 5 fluorouracil; N1 Octenoyl 5 fluorouracil; N1 Retinoyl 5 fluorouracil; Solubility in silicone oil

Indexed keywords

BUFFER; FLUOROURACIL; FLUOROURACIL DERIVATIVE; PHOSPHATE; PRODRUG; RETINOIC ACID; SILICONE OIL;

ARTICLE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; LIPOPHILICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; VITREORETINOPATHY;

EID: 0038699623     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00232-1     Document Type: Article

References (37)

1. Aguirrebena A., Saornil M.A., Giraldo A., Pastor J.C. Incidencia de la vitreoretinopatia proliferante (VRP) en el desprendimiento de retina regmatogeno. Arch. Soc. Esp. Oftalmol. 51:1986;229-234.
2. Araiz J.J., Refojo M.F., Arroyo M.H., Leong F.-L., Albert D.M., Tolentino F.I. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 34:1993;522-530.
3. Asaria R.H.Y., Kon C.H., Bunce C., Charteris D.G., Wong D., Khaw P.T., Aylward G.W. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy. Results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 108:2001;1179-1183.
4. Beall H.D., Prankerd R.J., Sloan K.B. 1-Alkylcarbonyl-5-fluorouracil prodrugs: synthesis, thermal and hydrolytic stability. Drug Dev. Ind. Pharm. 22:1996;85-90.
5. Berger A.S., Cheng C.-K., Pearson P.A., Ashton P., Crooks P.A., Cynkowski T., Cynkowska G., Jaffe G.J. Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 37:1996;2318-2325.
6. Binder S., Riss B., Skorpik C., Kulnig W. Inhibition of experimental intraocular proliferation with intravitreal 5-fluorouracil. Graefes Arch. Clin. Exp. Ophthalmol. 221:1983;126-129.
7. Blumenkranz M.S., Ophir A., Claflin A.J., Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. J. Ophthalmol. 94:1982;458-467.
8. Blumenkranz M.S., Claflin A., Hajek A.S. Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation. Arch. Ophthalmol. 102:1984a;598-604.
9. Blumenkranz M., Hernandez E., Ophir A., Norton E.W.D. 5-Fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology. 91:1984b;122-130.
10. Buur A., Bundgaard H. Prodrugs of 5-fluorouracil. I. Hydrolysis kinetics and physicochemical properties of various N-acyl derivatives of 5-fluorouracil. Int. J. Pharm. 21:1984;349-364.
11. Chen M., Lan P., Gao M. Effects of epidermal growth factor, basic fibroblast growth factor and 5-fluorouracil on human retinal pigment epithelial wound closure in vitro. Chung Hua Yen Ko Tsa Chih. 35:1999;134-136. (in Chinese).
12. Doyle J.W., Dowgiert R.K., Buzney S.M. Factors modulating the effect of retinoids on cultured retinal pigment epithelial cell proliferation. Curr. Eye Res. 11:1992;753-765.
13. Fekrat S., de Juan E., Campochiaro P.A. The effect of oral 13-cis-retinoic acid on retinal detachment after surgical repair in eyes with proliferative vitreoretinopathy. Ophthalmology. 102:1995;412-418.
14. Giordano G.G., Refojo M.F., Arroyo M.H. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest. Ophthalmol. Vis. Sci. 34:1993;2743-2751.
15. Herrero-Vanrell R., Refojo M.F. Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52:2001;5-16.
16. Jarus G., Blumenkranz M., Hernandez E., Sossi N. Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. Ophthalmology. 92:1985;91-96.
17. Jolimaître P., André-Barres C., Malet-Martino M., Martino R., Rico-Lattes I. A new method for the synthesis of 5-fluorouracil prodrugs. Synlett. 11:1999;1829-1831.
18. Martino R., Malet-Martino M., Gilard V. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr. Drug Metab. 1:2000;271-303.
19. Meynial D., Lopez A., Malet-Martino M., Hoffmann J.S., Martino R. Application of fluorine-19 nuclear magnetic resonance to the determination of plasma-protein binding of 5′-deoxy-5-fluorouridine, a new antineoplastic fluoropyrimidine. J. Pharm. Biomed. Anal. 6:1988;47-59.
20. Mietz H., Heimann K. Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal diseases. Br. J. Ophthalmol. 79:1995;874-877.
21. Nagasaki H., Shinagawa K., Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog. Ret. Eye Res. 17:1998;77-98.
22. Nakagawa M., Refojo M.F., Marin J.F., Doi M., Tolentino F.I. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 36:1995;2388-2395.
23. Ophir A. Further observations on the prevention of experimental proliferative vitreoretinopathy by 5-fluorouracil. Ophthalmic Res. 23:1991;128-132.
24. Pastor J.C. Proliferative vitreoretinopathy: an overview. Surv. Ophtalmol. 43:1998;3-18.
25. Pastor J.C., Rodriguez de la Rua E., Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog. Retin. Eye Res. 21:2002;127-144.
26. Perkins S.L., Gallemore R.P., Yang C.H., Guo H., Ashton P., Jaffe G.J. Pharmacokinetics of the fluocinolone/5-fluorouracil codrug in the gas-filled eye. Retina. 20:2000;514-519.
27. Rubsamen P.E., Davis P.A., Hernandez E., O'Grady G.E., Cousins S.W. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol. 112:1994;407-413.
28. Steffansen B., Ashton P., Buur A. Intraocular drug delivery. In vitro release studies of 5-fluorouracil from N1-alkoxycarbonyl prodrugs in silicone oil. Int. J. Pharm. 132:1996;243-250.
29. Stern W.H., Guerin C.J., Erickson P.A., Lewis G.P., Anderson D.H., Fisher S.K. Ocular toxicity of fluorouracil after vitrectomy. Am. J. Ophthalmol. 96:1983a;43-51.
30. Stern W.H., Lewis G.P., Erickson P.A., Guerin C.J., Anderson D.H., Fisher S.K., O'Donnell J.J. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am. J. Ophthalmol. 96:1983b;33-42.
31. Sunalp M., Wiedemann P., Sorgente N., Ryan S.J. Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model. Curr. Eye Res. 3:1984;619-623.
32. Takahashi M., Refojo M.F., Nakagawa M., Veloso A., Leong F.-L. Antiproliferative effect of retinoic acid in 1% sodium hyaluronate in an animal model of PVR. Curr. Eye Res. 16:1997;703-709.
33. Veloso A.A.S., Kadrmas E.F., Larrosa J.M., Sandberg M.A., Tolentino F.I., Refojo M.F. 13-cis-Retinoic acid in silicone-fluorosilicone copolymer oil in a rabbit model of proliferative vitreoretinopathy. Exp. Eye Res. 65:1997;425-434.
34. Viswanadhan V.N., Ghose A.K., Revankar G.R., Robins R.K. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci. 29:1989;163-172.
35. Ward T., Hartzer M., Blumenkranz M., Lin L.-R. A comparison of 5-fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring. Curr. Eye Res. 12:1993;397-401.
36. Yamamoto S., Takeuchi S. Silicone oil and fluorosilicone. Semin. Ophthalmol. 15:2000;15-24.
37. Yang C.-S., Khawly J.A., Hainsworth D.P., Chen S.-N., Ashton P., Guo H., Jaffe G.J. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. 116:1998;69-77.